Bimekizumab in Psoriasis: 3-Year Outcomes - Top-Institutions - MDSpire

Bimekizumab in Psoriasis: 3-Year Outcomes

Investigators compare patient-reported symptoms and quality-of-life outcomes vs secukinumab.

  • By

  • Kathryn Wighton

  • March 12, 2026

  • 5 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Dermatology
    • Clinical Trials
    • Immunology

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Dermatology
    • Immunodermatology
    • Clinical Research

  • #3

    Massachusetts General Hospital (MGH)
    Massachusetts General Hospital (MGH)

    Boston, MA

    Key Differentiators

    • Dermatology
    • Clinical Trials
    • Immunology

  • #4

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Dermatology
    • Clinical Research
    • Immunology

  • #5

    Stanford University Medical Center
    Stanford University Medical Center

    Stanford, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Trials

Original Source(s)

Bimekizumab in Psoriasis: 3-Year Outcomes

  • by Kathryn Wighton

  • March 12, 2026

Related Content

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial

Inhibition of TYK2 in Skin Autoimmune Disorders: Achieving Remission of Discoid Lupus and Psoriasis with Deucravacitinib and Complementary Confocal Microscopy Evidence

Biologics Tied to Lower Eye Risk in Psoriasis

Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy.